Literature DB >> 27709309

Suitable Concentrations of Uric Acid Can Reduce Cell Death in Models of OGD and Cerebral Ischemia-Reperfusion Injury.

Bin Zhang1, Ning Yang2, Shao-Peng Lin3, Feng Zhang4.   

Abstract

Cerebral infarction (CI) is a common clinical cerebrovascular disease, and to explore the pathophysiological mechanisms and seek effective treatment means are the hotspot and difficult point in medical research nowadays. Numerous studies have confirmed that uric acid plays an important role in CI, but the mechanism has not yet been clarified. When treating HT22 and BV-2 cells with different concentrations of uric acid, uric acid below 450 μM does not have significant effect on cell viability, but uric acid more than 500 μM can significantly inhibit cell viability. After establishing models of OGD (oxygen-glucose deprivation) with HT22 and BV-2 cells, uric acid at a low concentration (50 μM) cannot improve cell viability and apoptosis, and Reactive oxygen species (ROS) levels during OGD/reoxygenation; a suitable concentration (300 μM) of uric acid can significantly improve cell viability and apoptosis, and reduce ROS production during OGD/reoxygenation; but a high concentration (1000 μM) of uric acid can further reduce cell viability and enhance ROS production. After establishing middle cerebral artery occlusion of male rats with suture method, damage and increase of ROS production in brain tissue could be seen, and after adding suitable concentration of uric acid, the degree of brain damage and ROS production was reduced. Therefore, different concentrations of uric acid should have different effect, and suitable concentrations of uric acid have neuroprotective effect, and this finding may provide guidance for study on the clinical curative effect of uric acid.

Entities:  

Keywords:  Cerebral infarction; Cerebral ischemia–reperfusion injury; Microglial cells; Oxygen-glucose deprivation; Uric acid

Mesh:

Substances:

Year:  2016        PMID: 27709309     DOI: 10.1007/s10571-016-0430-8

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  28 in total

Review 1.  NADPH oxidases as therapeutic targets in ischemic stroke.

Authors:  Timo Kahles; Ralf P Brandes
Journal:  Cell Mol Life Sci       Date:  2012-05-23       Impact factor: 9.261

2.  Decrease in uric acid in acute ischemic stroke correlates with stroke severity, evolution and outcome.

Authors:  Raf Brouns; Annick Wauters; Gerda Van De Vijver; Didier De Surgeloose; Rishi Sheorajpanday; Peter P De Deyn
Journal:  Clin Chem Lab Med       Date:  2010-03       Impact factor: 3.694

3.  Uric acid levels are relevant in patients with stroke treated with thrombolysis.

Authors:  Sergio Amaro; Xabier Urra; Manuel Gómez-Choco; Víctor Obach; Alvaro Cervera; Martha Vargas; Ferran Torres; Jose Rios; Anna M Planas; Angel Chamorro
Journal:  Stroke       Date:  2010-12-16       Impact factor: 7.914

4.  Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke.

Authors:  Eduardo Romanos; Anna M Planas; Sergio Amaro; Angel Chamorro
Journal:  J Cereb Blood Flow Metab       Date:  2006-04-05       Impact factor: 6.200

5.  Serum uric acid and risk of ischemic stroke: the ARIC Study.

Authors:  Atsushi Hozawa; Aaron R Folsom; Hassan Ibrahim; F Javier Nieto; Wayne D Rosamond; Eyal Shahar
Journal:  Atherosclerosis       Date:  2005-10-18       Impact factor: 5.162

6.  The URICO-ICTUS study, a phase 3 study of combined treatment with uric acid and rtPA administered intravenously in acute ischaemic stroke patients within the first 4.5 h of onset of symptoms.

Authors:  Sergio Amaro; David Cánovas; Mar Castellanos; Jaime Gállego; Joan Martí-Fèbregas; Tomás Segura; Angel Chamorro
Journal:  Int J Stroke       Date:  2010-08       Impact factor: 5.266

7.  Course of matrix metalloproteinase-9 isoforms after the administration of uric acid in patients with acute stroke: a proof-of-concept study.

Authors:  Sergio Amaro; Víctor Obach; Alvaro Cervera; Xabier Urra; Manuel Gómez-Choco; Anna M Planas; Angel Chamorro
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

8.  Is elevated SUA associated with a worse outcome in young Chinese patients with acute cerebral ischemic stroke?

Authors:  Bin Zhang; Cong Gao; Ning Yang; WeiZhi Zhang; XingWang Song; JianRui Yin; ShuXiang Pu; YongHong Yi; QingChun Gao
Journal:  BMC Neurol       Date:  2010-09-18       Impact factor: 2.474

9.  Decreased uric acid levels correlate with poor outcomes in acute ischemic stroke patients, but not in cerebral hemorrhage patients.

Authors:  Hongliang Wu; Qian Jia; Gaifen Liu; Liping Liu; Yuehua Pu; Xingquan Zhao; Chunxue Wang; Yilong Wang; Yongjun Wang
Journal:  J Stroke Cerebrovasc Dis       Date:  2013-06-02       Impact factor: 2.136

Review 10.  National stroke registries for monitoring and improving the quality of hospital care: A systematic review.

Authors:  Dominique A Cadilhac; Joosup Kim; Natasha A Lannin; Moira K Kapral; Lee H Schwamm; Martin S Dennis; Bo Norrving; Atte Meretoja
Journal:  Int J Stroke       Date:  2016-01       Impact factor: 5.266

View more
  12 in total

Review 1.  A new era for stroke therapy: Integrating neurovascular protection with optimal reperfusion.

Authors:  Ligen Shi; Marcelo Rocha; Rehana K Leak; Jingyan Zhao; Tarun N Bhatia; Hongfeng Mu; Zhishuo Wei; Fang Yu; Susan L Weiner; Feifei Ma; Tudor G Jovin; Jun Chen
Journal:  J Cereb Blood Flow Metab       Date:  2018-09-07       Impact factor: 6.200

2.  Uric Acid Neuroprotection Associated to IL-6/STAT3 Signaling Pathway Activation in Rat Ischemic Stroke.

Authors:  Alicia Aliena-Valero; Sergio Rius-Pérez; Júlia Baixauli-Martín; Germán Torregrosa; Ángel Chamorro; Salvador Pérez; Juan B Salom
Journal:  Mol Neurobiol       Date:  2020-09-22       Impact factor: 5.590

Review 3.  Effect of uric acid in animal models of ischemic stroke: A systematic review and meta-analysis.

Authors:  Alicia Aliena-Valero; Júlia Baixauli-Martín; María Castelló-Ruiz; Germán Torregrosa; David Hervás; Juan B Salom
Journal:  J Cereb Blood Flow Metab       Date:  2020-11-19       Impact factor: 6.200

4.  The protective effect of uric acid in reducing TLR4/NF-κB activation through the inhibition of HMGB1 acetylation in a model of ischemia-reperfusion injury in vitro.

Authors:  Guan-Mei Cheng; Ruo-Lu Wang; Bin Zhang; Xiao-Ying Deng
Journal:  Mol Biol Rep       Date:  2020-02-24       Impact factor: 2.316

5.  Evaluation of efficacy and safety of Reteplase and Alteplase in the treatment of hyper-acute cerebral infarction.

Authors:  Zhi-Jian Lin; Hong-Yan Qiu; Xiao-Xin Tong; Yi Guo; Man-Fu Han; Chun-Shui Yang; Kai-Hua Lin; Jun Wu; Xing Li; Yang Yang
Journal:  Biosci Rep       Date:  2018-01-17       Impact factor: 3.840

6.  Relationship between Uric Acid Level and Severity of Acute Primary Cerebral Infarction: A Cross-Sectional Study.

Authors:  Ruying Wang; Yi Zhong; Quan Zhou; Ping Xu
Journal:  Biomed Res Int       Date:  2020-06-22       Impact factor: 3.411

7.  Uric acid promotes oxidative stress and enhances vascular endothelial cell apoptosis in rats with middle cerebral artery occlusion.

Authors:  Chengfu Song; Xiangdong Zhao
Journal:  Biosci Rep       Date:  2018-05-15       Impact factor: 3.840

8.  Serum Uric Acid and Triglycerides in Chinese Patients with Newly Diagnosed Moyamoya Disease: A Cross-Sectional Study.

Authors:  Wenyuan Ma; Changmeng Cui; Song Feng; Genhua Li; Guangkui Han; Yawei Hu; Xiang Li; Jianwei Lv; Chen Liu; Feng Jin
Journal:  Biomed Res Int       Date:  2019-07-02       Impact factor: 3.411

9.  Verification and comparison of three prediction models of ischemic stroke in young adults based on the back propagation neural networks.

Authors:  Yuyang Chen; Yingqi Mao; Xiaoyun Pan; Weifeng Jin; Tao Qiu
Journal:  Medicine (Baltimore)       Date:  2021-03-19       Impact factor: 1.817

10.  Factors Influencing the Serum Uric Acid in Gout with Cerebral Infarction.

Authors:  Yi Li; Hongyi Yang; Yao Tian; Lihua Duan
Journal:  Mediators Inflamm       Date:  2021-07-12       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.